Sort   by:  
 Page size 
ProteomicsBiopsy proteome score performs well as an effect measure in a gluten-challenge trial of coeliac disease
Objective Development of novel treatments for coeliac disease (CeD) is dependent on precise tools to monitor changes in gluten-induced mucosal damage. Current histology measures are subjective and difficult to standardise. Biopsy proteome scoring is an objective alternative to histology which is bas...
ORGANISM(S): Homo sapiens (Human) 
2025-04-08 | PXD050655 | Pride
Human Proteome score Gut biopsy Evosep Timstofflex Clinical trial 
ProteomicsQuantitative proteomics of coeliac gut during 14-day gluten challenge: low-level baseline inflammation despite clinical and histological normality predicts subsequent response
Coeliac disease is a small intestinal disorder caused by an abarrent immune response towards dietary gluten due to activation of pro-inflammatory gluten specific CD4+ T cells. Histological evaluation and classification of gluten induced musosal changes is part of the diagnostic work up. of adults. ...
ORGANISM(S): Homo sapiens (Human) 
2021-03-03 | PXD018977 | Pride
Coeliac disese Lc-msms Proteomics Human intestine Ffpe Laser capture microdissection Gluten challenge 
GenomicsRNA-sequencing of gluten-reactive and non-reactive T-cells from blood samples of treated CeD patients during a gluten-challenge
Gluten-specific CD4+ T cells are drivers of celiac disease (CeD). Here we aimed to characterize such cells in blood of treated CeD patients during gluten challenge with comparison to similar cells of untreated disease. Treated CeD patients underwent a 3-day gluten-challenge with blood sampling at b...
EGAS00001004988 | EGA
Genomics
Gluten Challenge
PRJNA778253 | ENA
GenomicsPBMC gene expression profiles in diet treated celiac disease upon oral gluten challenge
We aimed to study the molecular impact of short gluten exposure in GFD treated CD patients, as well as identify biological pathways that remain altered in CD regardless of treatment. We used STRT/C1 (single-cell tagged reverse transcription), a 5’-end RNA sequencing method, suitable for quick a...
EGAS00001004860 | EGA
ProteomicsPlasma Proteomics Analysis of a Transglutaminase 2 inhibitor in Celiac Disease
Individuals with celiac disease (CeD) on a long-term gluten-free diet (GFD) underwent a 6-week gluten challenge combined with 100mg per day of the transglutaminase 2 enzyme -inhibitor, ZED1227 (PGCd, n = 28) or placebo (PGCp, n = 19). The samples were collected at baseline (GFD) and post-gluten chal...
ORGANISM(S): Homo sapiens (Human) 
2026-06-15 | PXD069597 | Pride
Human Lc_msms Celiac disease Plasma 
UnknownEvaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.
Not available
S-EPMC7878429 | biostudies-literature
TranscriptomicsGenome-wide analysis of B and T cell gene expression during a six-week gluten challenge in patients with celiac disease
Dietary gluten proteins (prolamins) from wheat, rye, and barley are the driving forces behind celiac disease, an organ-specific autoimmune disorder that targets both the small intestine and organs outside the gut. In the small intestine, gluten induces inflammation and a typical morphological change...
ORGANISM(S): Homo sapiens 
2017-01-27 | GSE87629 | GEO
UnknownA Clinician's Guide to Gluten Challenge.
Not available
S-EPMC10872809 | biostudies-literature
UnknownLack of Effect of Gluten Challenge on Fecal Microbiome in Patients With Celiac Disease and Non-Celiac Gluten Sensitivity.
Not available
S-EPMC8691493 | biostudies-literature
Sort   by:  
 Page size